Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pneumovax 23 in elderly population
NCT00307008Phase 2Completed
- Sponsor
- GSK
- Start
- Oct 2003
- Primary completion
- Feb 2005
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Streptococcus pneumoniae type 19f capsular polysaccharide antigen in pneumococcal disease, sponsored by GSK. Primary endpoint: Response rate to 11 vaccine serotypes at 1 month. Started Oct 2003; status: completed.
02
Drugs
Streptococcus pneumoniae type 19f capsular polysaccharide antigen
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT00307008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00307008.